What is zasocitinib, the once-daily psoriasis pill the FDA is fast-tracking?

Zasocitinib is an investigational once-daily oral medicine for moderate-to-severe plaque psoriasis; the FDA has accepted its application for Priority Review. That status shortens the agency’s review target because the therapy may offer a meaningful advance—it is not an approval and does not prove the drug is right for any individual. Patients should discuss established options with a dermatologist and wait for the FDA decision and full prescribing information before treating it as available.